Alloimmune-induced intragraft lymphoid neogenesis promotes B-cell tolerance breakdown that accelerates chronic rejection

Current Opinion in Organ Transplantation

Volumn 21, Issue 4, 2016, Pages 368-374

  Sicard, Antoine ^a,b,c   Chen, Chien Chia ^b   Morelon, Emmanuel ^a,b,c   Thaunat, Olivier ^a,b,c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Alloantibodies; Antibody mediated rejection; Antihuman leukocyte antigen antibodies; Autoantibodies; Chronic rejection; Lymphoid neogenesis; Tertiary lymphoid organs

Indexed keywords

AUTOANTIGEN; CELL SURFACE PROTEIN; LEUKOCYTE ANTIGEN; ALLOANTIBODY; HLA ANTIGEN;

ADAPTIVE IMMUNITY; ALLOGRAFT; ALLOIMMUNITY; ANTIBODY MEDIATED REJECTION; ANTIGEN ANTIBODY COMPLEX; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL FUNCTION; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; INTRAGRAFT LYMPHOID NEOGENESIS; LYMPHOID TISSUE; ORGAN TRANSPLANTATION; REVIEW; SOLID ORGAN TRANSPLANTATION; TISSUE REGENERATION; ALLOTRANSPLANTATION; CHRONIC DISEASE; GRAFT REJECTION; IMMUNOLOGY;

B-LYMPHOCYTES; CHRONIC DISEASE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; LYMPHOID TISSUE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84973349398     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000329     Document Type: Review

References (94)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739.
2. Jeannet M, Pinn VW, Flax MH, et al. Humoral antibodies in renal allotrans-plantation in man. N Engl J Med 1970; 282:111-117.
3. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994; 152:5135-5141.
4. Gebel HM, Liwski RS, Bray RA. Technical aspects of HLA antibody testing. Curr Opin Organ Transplant 2013; 18:455-462.
5. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012; 8:348-357.
6. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013; 381:313-319.
7. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21:1398-1406.
8. Cantarovich D, De Amicis S, Akl A, et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant 2011; 11:2737-2746.
9. Mittal S, Page SL, Friend PJ, et al. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure. Am J Transplant 2014; 14:1664-1671.
10. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30:252-269.
11. Wallace WD, Weigt SS, Farver CF. Update on pathology of antibody-mediated rejection in the lung allograft. Curr Opin Organ Transplant 2014; 19:303-308.
12. O'Leary JG, Demetris AJ, Friedman LS, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014; 14:779-787.
13. Gupta G, Abu Jawdeh BG, Racusen LC, et al. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation 2014; 97:1240-1246.
14. Sicard A, Ducreux S, Rabeyrin M, et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2014; 26:457-467.
15. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9:2520-2531.
16. Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, et al. 'Natural' human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86:1111-1115.
17. Sicard A, Amrouche L, Suberbielle C, et al. Outcome of kidney transplantations performed with preformed donor-specific antibodies of unknown etiology. Am J Transplant 2013; 14:193-201.
18. Thaunat O, Koenig A, Leibler C, Grimbert P. Effect of immunosuppressive drugs on humoral allosensitization after kidney transplant. J Am Soc Nephrol 2016; doi:10.1681/ASN.2015070781 [Epub ahead of print]
19. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000; 6:686-688.
20. Sicard A, Phares TW, Yu H, et al. The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients. Am J Transplant 2012; 12:1708-1719.
21. Olszewski WL. Pathophysiological aspects of lymphedema of human limbs: I. Lymph protein composition. Lymphat Res Biol 2004; 1:235-243.
22. Thaunat O, Louedec L, Dai J, et al. Direct and indirect effects of alloantibodies link neointimal and medial remodeling in graft arteriosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:2359-2365.
23. Smith RN, Kawai T, Boskovic S, et al. Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhu-man primates. Am J Transplant 2006; 6:1790-1798.
24. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant 2014; 19:33-40.
25. Bian H, Reed EF. Alloantibody-mediated class I signal transduction in en-dothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. J Immunol 1999; 163:1010-1018.
26. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci USA 2007; 104:1301-1306.
27. Diebolder CA, Beurskens FJ, deJong RN, et al. Complementisactivated by IgG hexamers assembled at the cell surface. Science 2014; 343:1260-1263.
28. Fremeaux-Bacchi V, Legendre CM. The emerging role of complement inhibitors in transplantation. Kidney Int 2015; 88:967-973.
29. Hirohashi T, Uehara S, Chase CM, et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010; 10:510-517.
30. Hirohashi T, Chase CM, Pelle Della P, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12:313-321.
31. Venner JM, Hidalgo LG, Famulski KS, et al. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant 2015; 15:1336-1348.
32. Papadimitriou JC, Drachenberg CB, Munivenkatappa R, et al. Glomerular inflammation in renal allografts biopsies after the first year: cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation 2010; 90:1478-1485.
33. Croker BP, Clapp WL, Abu Shamat AR, et al. Macrophages and chronic renal allograft nephropathy. Kidney Int Suppl 1996; 57:S42-S49.
34. Fahim T, Böhmig GA, Exner M, et al. The cellular lesion of humoral rejection: predominant recruitment of monocytes to peritubular and glomerular capillaries. Am J Transplant 2007; 7:385-393.
35. Yell M, Muth BL, Kaufman DB, et al. C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation 2015; 99:1151-1155.
36. Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993; 178:661-667.
37. Lefaucheur C, Viglietti D, Bentlejewski C, et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 2015; 27:293-304.
38. Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21-50.
39. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471-478.
40. Quast I, Keller CW, Maurer MA, et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest 2015; 125:4160-4170.
41. Bachelet T, Couzi L, Lepreux S, et al. Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome. Am J Transplant 2013; 13:2855-2864.
42. Martin L, Guignier F, Mousson C, et al. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplant J 2003; 76:395-400.
43. Opelz G; Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365:1570-1576.
44. Grafft CA, Cornell LD, Gloor JM, et al. Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol Dial Transplant 2010; 25:307-310.
45. Collins AB, Chicano SL, Cornell LD, et al. Putative antibody-mediated rejection with C4d deposition in HLA-identical, ABO-compatible renal allografts. Transplant Proc 2006; 38:3427-3429.
46. Ahern AT, Artruc SB, DellaPelle P, et al. Hyperacute rejection of HLA-AB-identical renal allografts associated with B lymphocyte and endothelial reactive antibodies. Transplant J 1982; 33:103-106.
47. Tan JC, Wadia PP, Coram M, et al. H-Y antibody development associates with acute rejection in female patients with male kidney transplants. Transplantation 2008; 86:75-81.
48. Gratwohl A, Döhler B, Stern M, Opelz G. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet 2008; 372:49-53.
49. Hankey KG, Drachenberg CB, Papadimitriou JC, et al. MIC expression in renal and pancreatic allografts. Transplantation 2002; 73:304-306.
50. Zou Y, Stastny P, Süsal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357:1293-1300.
51. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408-415.
52. Quiroga I, Salio M, Koo DDH, et al. Expressionof MHC class I-related Chain B (MICB) molecules on renal transplant biopsies. Transplantation 2006; 81:1196-1203.
53. Lerut E, Van Damme B, Noizat-Pirenne F, et al. Duffy and Kidd blood group antigens: minor histocompatibility antigens involved in renal allograft rejection? Transfusion 2007; 47:28-40.
54. Dragun D, Philippe A, Catar R. Role of non-HLA antibodies in organ transplantation. Curr Opin Organ Transplant 2012; 17:440-445.
55. Sigdel TK, Sarwal MM. Moving beyond HLA: a review of nHLA antibodies in organ transplantation. Hum Immunol 2013; 74:1486-1490.
56. Win TS, Pettigrew GJ. Humoral autoimmunity and transplant vasculopathy: when allo is not enough. Transplantation 2010; 90:113-120.
57. Porcheray F, DeVito J, Yeap BY, et al. Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses. Transplantation 2010; 89:1239-1246.
58. Rose ML. Role of antivimentin antibodies in allograft rejection. Hum Immunol 2013; 74:1459-1462.
59. Joosten SA, Sijpkens YWJ, van Ham V, et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 2005; 5:383-393.
60. Hachem RR, Tiriveedhi V, Patterson GA, et al. Antibodies to K-a 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant 2012; 12:2164-2171.
61. Thaunat O, Graff-Dubois S, Fabien N, et al. A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection. Kidney Int 2012; 81:207-219.
62. Porcheray F, DeVito J, Helou Y, et al. Expansion of polyreactive B cells cross-reactive to HLA and self in the blood of a patient with kidney graft rejection. Am J Transplant 2012; 12:2088-2097.
63. Gao B, Rong C, Porcheray F, et al. Evidence to support a contribution of polyreactive antibodies to HLA serum reactivity. Transplantation 2016; 100:217-226.
64. Li L, Wadia P, Chen R, et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and 'antibo-dyome' measures. Proc Natl Acad Sci USA 2009; 106:4148-4153.
65. Le Bas-Bernardet S, Hourmant M, Coupel S, et al. Non-HLA-type endothelial cell reactive alloantibodies in pretransplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003; 3:167-177.
66. Jackson AM, Lucas DP, Melancon JK, Desai NM. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 2011; 92:54-60.
67. Perrey C, Brenchley PE, Johnson RW, Martin S. An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol 1998; 6:101-106.
68. Lucchiari N, Panajotopoulos N, Xu C, et al. Antibodies eluted from acutely rejected renal allografts bind to and activate human endothelial cells. Hum Immunol 2000; 61:518-527.
69. Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558-569.
70. Jackson AM, Sigdel TK, Delville M, et al. Endothelial cell antibodies associated with novel targets and increased rejection. J Am Soc Nephrol 2015; 26:1161-1171.
71. Iwata T, Philipovskiy A, Fisher AJ, et al. Antitype V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008; 181:5738-5747.
72. Fedoseyeva EV, Zhang F, Orr PL, et al. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol 1999; 162:6836-6842.
73. Banasik M, Boratyńska M, Kościelska-Kasprzak K, et al. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Transpl Int 2014; 27:1029-1038.
74. Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft failure in the presence of antiangiotensin II type-1 receptor antibodies. Am J Transplant 2013; 13:2577-2589.
75. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377.
76. Ota M, Duong BH, Torkamani A, et al. Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 2010; 185:4128-4136.
77. Hsu H-C, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9:166-175.
78. Schaffert H, Pelz A, Saxena A, et al. IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthe-nia gravis. Eur J Immunol 2015; 45:1339-1347.
79. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nature Immunol 2014; 14:447-462.
80. Kratz A, Campos-Neto A, Hanson MS, Ruddle NH. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 1996; 183:1461-1472.
81. Thaunat O, Field A-C, Dai J, et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci USA 2005; 102:14723-14728.
82. Thaunat O, Patey N, Morelon E, et al. Lymphoid neogenesis in chronic rejection: the murderer is in the house. Curr Opin Immunol 2006; 18:576-579.
83. Sato M, Hirayama S, Hwang DM, et al. The role of intrapulmonary de novo lymphoid tissue in obliterative bronchiolitis after lung transplantation. J Immunol 2009; 182:7307-7316.
84. Kerjaschki D, Regele HM, Moosberger I, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lympho-cytic infiltrates. J Am Soc Nephrol 2004; 15:603-612.
85. Di Carlo E, D'Antuono T, Contento S, et al. Quilty effect has the features of lymphoid neogenesis and shares CXCL13-CXCR5 pathway with recurrent acute cardiac rejections. Am J Transplant 2007; 7:201-210.
86. Wehner JR, Fox-Talbot K, Halushka MK, et al. B cells and plasma cells in coronaries of chronically rejected cardiac transplants. Transplantation 2010; 89:1141-1148.
87. Thaunat O. Pathophysiologic significance of B-cell clusters in chronically rejected grafts. Transplantation 2011; 92:121-126.
88. Thaunat O, Patey N, Caligiuri G, et al. Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J Immunol 2010; 185:717-728.
89. Deteix C, Attuil-Audenis V, Duthey A, et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol 2010; 184:5344-5351.
90. Thaunat O, Patey N, Gautreau C, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplant J 2008; 85:1648-1653.
91. Thaunat O, Kerjaschki D, Nicoletti A. Is defective lymphatic drainage a trigger for lymphoid neogenesis? Trends Immunol 2006; 27:441-445.
92. Motallebzadeh R, Rehakova S, Conlon TM, et al. Blocking lymphotoxin signaling abrogates the development of ectopic lymphoid tissue within cardiac allografts and inhibits effector antibody responses. FASEB J 2012; 26:51-62.
93. Win TS, Rehakova S, Negus MC, et al. Donor CD4 T cells contribute to cardiac allograft vasculopathy by providing help for autoantibody production. Circ Heart Fail 2009; 2:361-369.
94. Angaswamy N, Tiriveedhi V, Sarma NJ, et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol 2013; 74:1478-1485.